Prestige Consumer Healthcare : Q4 2024 Prestige Consumer Healthcare Inc. Earnings Conference Call Presentation

M a y 1 5 t h , 2 0 2 4

Full-Year FY 24 Results

Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's ability to execute on its marketing and brand-building strategy and to maximize shareholder value; the Company's expected growth, including with respect to consumption, online sales and international sales; the impact and timing of supply chain challenges; and the Company's capital allocation strategy, including its pursuit of M&A and further reductions to leverage. Words such as "anticipate," "continue," "further," "consistent," "will," "expect," "focus," "may," "should," "could," "would," and similar expressions

identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability of the Company's manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages; the impact of economic and business conditions; consumer trends; consumer trends; competitive pressures; the impact of the Company's advertising and promotional and new product development initiatives; customer inventory management initiatives; fluctuating foreign exchange rates; and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our May 14, 2024 earnings release in the "About Non-GAAP Financial Measures" section.

F U L L - Y E A R F Y 2 4 R E S U L T S

Agenda for Today's Discussion

1. FY 24 and Performance Recap

II. Diverse Portfolio Driving Growth

1. Financial Strategy & Capital Allocation IV. The Road Ahead & FY 25 Outlook

F U L L - Y E A R F Y 2 4 R E S U L T S

3

1. FY 24 and Performance Recap

F U L L - Y E A R F Y 2 4 R E S U L T S

Proven Strategy & Execution Delivered Strong FY 24 Results

FY 24 Sales

Drivers

Superior Earnings

and FCF

Disciplined Capital

Allocation

• Consistent performance in FY 24, with Organic Revenues(1) up slightly vs. PY
• Strong consumption growth; consumers continuing to seek out trusted brands
• Sales inhibited by temporary supply constraints late in Q4
• Gross Margin, Adj. EBITDA Margin(3) stable
• Adjusted EPS(3) flat vs. FY 23
• Leading FCF profile driving Free Cash Flow(3) generation
• Disciplined capital allocation resulting in leverage of 2.8x(4)
• Continued to assess capital deployment opportunities

F U L L - Y E A R F Y 2 4 R E S U L T S

5

Continued Active Management of Supply Chain

Well-Established

Long-Term

Competencies

Preparedness &

Readiness

Long-Term

Outlook

• Broad supply & sourcing is a key element of our strategy
• Have been managing 100+ global supply partners for many years, with long-term trusted relationships
• Q4 supply challenges driven primarily by limited Eye Care supply
• Primary and secondary suppliers faced simultaneous operational interruptions
• Q4 supply chain constraints reaffirmed recent strategic manufacturing decisions
• Continue to execute on continuity strategy to ensure future readiness
• Working hand in hand with trusted suppliers to ensure essential supply
• Taking partnership approach in supporting third parties to ensure limited business impacts

F U L L - Y E A R F Y 2 4 R E S U L T S

6

Long-Term Proven Business Attributes Unchanged

Diverse

Portfolio

Diverse portfolio of category

leading brands

		Oral Care
Analgesics	9%	Women's
Cough /	10%	Health

Cold		21%
	11%
Skin	12%
	21%
Care
	16%	GI
	Eye &
	Ear Care

Brand

Building

Brand-building enabling strong

consumption across iconic portfolio

Capital

Allocation

Lower leverage driving increased optionality

around long-term capital allocation

Leverage(4)

5.0x
	2.8x
FY 19	FY 24

Consistent Strategy & Execution Delivering Superior Performance:

+6.1% 3-Year Revenue CAGR & +9.1% 3-Year Adjusted EPS(3) CAGR

FY 24 Revenues; Other OTC not shown (less than 1%)

F U L L - Y E A R F Y 2 4 R E S U L T S

7

II. Diverse Portfolio

Driving Growth

F U L L - Y E A R F Y 2 4 R E S U L T S

Long-Term Performance Enabled by Brand-Building Strategy

Understanding Consumer Insights and Opportunity

2 Flexible & Agile Brand Strategies Responsive to Consumer Needs

3 E-Commerce Success through Investments

4 Consumer-Driven New Product Development

Resulting Long-Term Success Across Channels & Categories

F U L L - Y E A R F Y 2 4 R E S U L T S

9

Numerous Drivers of Success Across Categories

Eye & Ear Care

Skin Care

GI

Omnichannel Campaigns & Innovation Attuned to Consumer Needs

Driving Consumption Growth

F U L L - Y E A R F Y 2 4 R E S U L T S

10